Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial: version 1; peer review: 3 approved

Background: By the early 1980s, tuberculosis treatment was shortened from 24 to 6 months, maintaining relapse rates of 1-2%. Subsequent trials attempting shorter durations have failed, with 4-month arms consistently having relapse rates of 15-20%. One trial shortened treatment only among those witho...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gates open research 2017-11
Hauptverfasser:	Chen, Ray Y, Via, Laura E, Dodd, Lori E, Walzl, Gerhard, Malherbe, Stephanus T, Loxton, André G, Dawson, Rodney, Wilkinson, Robert J, Thienemann, Friedrich, Tameris, Michele, Hatherill, Mark, Diacon, Andreas H, Liu, Xin, Xing, Jin, Jin, Xiaowei, Ma, Zhenya, Pan, Shouguo, Zhang, Guolong, Gao, Qian, Jiang, Qi, Zhu, Hong, Liang, Lili, Duan, Hongfei, Song, Taeksun, Alland, David, Tartakovsky, Michael, Rosenthal, Alex, Whalen, Christopher, Duvenhage, Michael, Cai, Ying, Goldfeder, Lisa C, Arora, Kriti, Smith, Bronwyn, Winter, Jill, Barry, Clifton E, Predict TB Study Group
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Clinical trials Disease prevention Drug dosages Hypotheses Medical imaging TNF inhibitors Tuberculosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background: By the early 1980s, tuberculosis treatment was shortened from 24 to 6 months, maintaining relapse rates of 1-2%. Subsequent trials attempting shorter durations have failed, with 4-month arms consistently having relapse rates of 15-20%. One trial shortened treatment only among those without baseline cavity on chest x-ray and whose month 2 sputum culture converted to negative. The 4-month arm relapse rate decreased to 7% but was still significantly worse than the 6-month arm (1.6%, P
ISSN:	2572-4754 2572-4754
DOI:	10.12688/gatesopenres.12750.1